tiprankstipranks
Advertisement
Advertisement

CAPR Stock Latest News

Capricor files suit against NS Pharma over Deramiocel distribution deal
The FlyCapricor files suit against NS Pharma over Deramiocel distribution deal
2d ago
CAPR
Capricor Sues NS Pharma Over Deramiocel U.S. Rights
PremiumCompany Announcements
Capricor Sues NS Pharma Over Deramiocel U.S. Rights
2d ago
8K
CAPR
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 3/30/26, According to Analysts
PremiumMarket News
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 3/30/26, According to Analysts
1M ago
XEL
CAPR
Capricor Therapeutics price target raised to $43 from $41 at Roth Capital
PremiumThe Fly
Capricor Therapeutics price target raised to $43 from $41 at Roth Capital
2M ago
CAPR
Capricor Therapeutics Nears Key Milestones After Earnings Call
PremiumCompany Announcements
Capricor Therapeutics Nears Key Milestones After Earnings Call
2M ago
CAPR
Capricor selloff today a buying opportunity, says Roth Capital
PremiumThe FlyCapricor selloff today a buying opportunity, says Roth Capital
2M ago
CAPR
Capricor Therapeutics price target raised to $51 from $48 at Alliance Global
Premium
The Fly
Capricor Therapeutics price target raised to $51 from $48 at Alliance Global
2M ago
CAPR
Capricor Therapeutics price target raised to $63 from $50 at B. Riley
Premium
The Fly
Capricor Therapeutics price target raised to $63 from $50 at B. Riley
2M ago
CAPR
Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler
PremiumThe Fly
Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler
2M ago
CAPR
Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)
PremiumThe Fly
Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)
2M ago
CAPR
Capricor Therapeutics options imply 4.2% move in share price post-earnings
PremiumThe Fly
Capricor Therapeutics options imply 4.2% move in share price post-earnings
2M ago
CAPR
Deramiocel’s De‑Risked Path to Approval and Expanded DMD Opportunity Underpin Buy on CAPR
PremiumRatings
Deramiocel’s De‑Risked Path to Approval and Expanded DMD Opportunity Underpin Buy on CAPR
2M ago
CAPR
Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial
PremiumThe FlyCapricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial
2M ago
CAPR
Midday Fly By: HP Enterprise reports Q1 beat, BioNTech announces new company
Premium
The Fly
Midday Fly By: HP Enterprise reports Q1 beat, BioNTech announces new company
2M ago
ABM
CNC
Capricor Advances Deramiocel BLA Review for Duchenne DMD
Premium
Company Announcements
Capricor Advances Deramiocel BLA Review for Duchenne DMD
2M ago
8K
CAPR
Capricor announces establishment of new PDUFA date for dermiocel BLA
PremiumThe Fly
Capricor announces establishment of new PDUFA date for dermiocel BLA
2M ago
CAPR
CAPR Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CAPR Earnings this Week: How Will it Perform?
2M ago
CAPR
FDA review process for accelerated approval narrows, less predictable, WSJ says
PremiumThe Fly
FDA review process for accelerated approval narrows, less predictable, WSJ says
2M ago
CAPR
IRON
Capricor expects to submit updates to BLA in February 2026
PremiumThe Fly
Capricor expects to submit updates to BLA in February 2026
4M ago
CAPR
Capricor Therapeutics: HOPE-3 Success, De-Risked Regulatory Path, and Priority Review Voucher Upside Support Buy Rating
PremiumRatingsCapricor Therapeutics: HOPE-3 Success, De-Risked Regulatory Path, and Priority Review Voucher Upside Support Buy Rating
4M ago
CAPR
Capricor Therapeutics price target raised to $50 from $21 at B. Riley
Premium
The Fly
Capricor Therapeutics price target raised to $50 from $21 at B. Riley
5M ago
CAPR
Capricor Therapeutics price target raised to $45 from $20 at Piper Sandler
Premium
The Fly
Capricor Therapeutics price target raised to $45 from $20 at Piper Sandler
5M ago
CAPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >